Lantheus Holdings Inc
$ 75.43
-0.38%
26 Feb - close price
- Market Cap 5,148,517,000 USD
- Current Price $ 75.43
- High / Low $ 80.91 / 74.60
- Stock P/E 31.42
- Book Value 16.88
- EPS 2.41
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.10 %
- ROE 0.15 %
- 52 Week High 111.29
- 52 Week Low 47.25
About
Lantheus Holdings, Inc. develops, manufactures and markets diagnostic and therapeutic agents and products that assist physicians in the diagnosis and treatment of heart, cancer and other diseases worldwide. The company is headquartered in North Billerica, Massachusetts.
Analyst Target Price
$85.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-11-06 | 2025-08-06 | 2025-04-30 | 2025-02-20 | 2024-11-06 | 2024-07-31 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0 | 1.27 | 1.57 | 1.53 | 1.59 | 1.7 | 1.8 | 1.69 | 1.75 | 1.47 | 1.54 | 1.47 |
| Estimated EPS | 1.16 | 1.28 | 1.67 | 1.6539 | 1.5431 | 1.56 | 1.83 | 1.54 | 1.45 | 1.32 | 1.31 | 1.26 |
| Surprise | -1.16 | -0.01 | -0.1 | -0.1239 | 0.0469 | 0.14 | -0.03 | 0.15 | 0.3 | 0.15 | 0.23 | 0.21 |
| Surprise Percentage | -100% | -0.7813% | -5.988% | -7.4914% | 3.0393% | 8.9744% | -1.6393% | 9.7403% | 20.6897% | 11.3636% | 17.5573% | 16.6667% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.94 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LNTH
2026-02-26 17:52:36
Lantheus (NASDAQ:LNTH) surpassed Q4 CY2025 revenue expectations with sales up 4% year-on-year to $406.8 million and reported non-GAAP profit of $1.67 per share, beating consensus estimates by 42.9%. Despite this, the company's full-year revenue and adjusted EPS guidance for 2026 fell short of analyst estimates, contributing to a weaker overall quarter and an immediate stock price decline of 2.9%.
2026-02-26 14:52:36
Lantheus Holdings recently provided 2026 revenue guidance of US$1.40 billion to US$1.45 billion, ahead of its Q4 2025 earnings report which is expected to show a year-on-year revenue decline. This guidance focuses investor attention on how the company's radiopharmaceutical portfolio will manage pricing pressures and product concentration risks, particularly around its PYLARIFY product. The new outlook suggests a recalibration due to softening PSMA PET trends, highlighting the importance of upcoming presentations to clarify how new products and strategic moves will affect growth and risk.
2026-02-26 13:52:36
Lantheus Holdings Inc. reported strong fourth-quarter results, with a net profit of $54.1 million and adjusted earnings of $1.67 per share, significantly exceeding analysts' expectations. The company also surpassed revenue forecasts, generating $406.8 million. Looking ahead, Lantheus projects annual earnings between $5 and $5.25 per share and revenue ranging from $1.4 billion to $1.45 billion.
2026-02-26 12:55:00
LANTHEUS HOLDINGS ($LNTH) reported strong Q4 2025 earnings, significantly beating both earnings per share and revenue estimates. The company posted earnings of $1.67 per share against an estimate of $1.19, and revenue of $406.79 million compared to an estimated $375.18 million. The report also details recent hedge fund activity, government contracts received, and analyst ratings, with multiple firms issuing buy or outperform ratings and a median price target of $79.0.
2026-02-26 12:52:36
Lantheus Holdings (LNTH) reported strong financial results for Q4 and the full year 2025, with worldwide revenue increasing by 4.0% in Q4 and reaching $1.54 billion for the full year. The company emphasized its strategic shift towards innovative radiodiagnostics, including the divestiture of its SPECT business and expansion of its PET portfolio. Lantheus provided a positive outlook for 2026, projecting revenue between $1.4 billion and $1.45 billion.
2026-02-25 16:51:38
Lantheus Holdings Inc. is set to release its Q4 and full-year 2025 earnings, with investors focused on how its Pylarify imaging agent is performing amid increased competition and the potential of its product pipeline. Analysts expect declines in EPS and revenue year-over-year, but Wall Street maintains a "strong buy" rating with an $85 price target. The company faces crucial FDA decisions for new formulations and imaging agents, along with a recent leadership transition, making 2026 a critical year for its growth strategy.
